Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

Direct-to-consumer advertising can be a controversial topic in the pharma industry. While the US isn’t the only other country ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The two organizations will provide multi-modal learning experiences, opportunities to work with peers, and more.

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...